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Gingival overgrowth (GO) is a side eﬀect associated with some distinct classes of drugs, such as anticonvulsants, immunosuppres-
sant, and calcium channel blockers. GO is characterized by the accumulation of extracellular matrix in gingival connective tissues,
particularly collagenous components, with varying degrees of inﬂammation. One of the main drugs associated with GO is the
antiepileptic phenytoin, which aﬀects gingival tissues by altering extracellular matrix metabolism. Nevertheless, the pathogenesis
of such drug-induced GO remains fulﬁlled by some contradictory ﬁndings. This paper aims to present the most relevant studies
regarding the molecular, immune, and inﬂammatory aspects of phenytoin-induced gingival overgrowth.
1.Introduction
Gingival overgrowth (GO) comprises any clinical condition
in which an increase in the size of the gingiva is observed.
Such enlargement can be caused by a multitude of stimuli
and stands as a singular complaint in the dental oﬃce.
Among the drugs that induce GO, the antiepileptic agent
phenytoin has been widely related to this condition [2].
Epilepsy is the most common chronic neurological dis-
orderinhumans[2].Theprevalenceofepilepsyindeveloped
countries reaches approximately 1%, rising to 2% in less de-
veloped nations [3]. Epilepsy treatment is based on drug-
therapies which aim to help patients to achieve seizure free-
dom without adverse eﬀects. However, in several cases the
ﬁrst-choicedrugfailsinthetreatmentduetoalackofeﬃcacy
or to the patient failure to tolerate the medication side eﬀects
[4, 5].
The ﬁrst report of GO associated with the chronic use of
phenytoin was made in 1939 [6]. This agent remains as one
of the most commonly prescribed medications to treat ep-
ilepsy and it may also be used in cases of neuralgias and car-
diac arrhythmias [7]. It is estimated that about 30 to 50% of
patients taking phenytoin develop signiﬁcant gingival alter-
ations [8].
OtheranticonvulsantshavealsobeenassociatedwithGO.
Nevertheless, the cases of gingival changes after chronic
use of valproic acid, carbamazepine, phenobarbital and vi-
gabatrin in adult patients have been rarely reported [9–
11]. Other classes of drugs, such as the immunosuppressant
cyclosporineAandsomecalciumchannelblockers(dihydro-
piridines, diltiazem and verapamil) also have GO as an im-
portant adverse eﬀect [12].
To date several studies have tried to determine the path-
ogenesis of drug-induced GO but the mechanisms that trig-
ger such condition are not fully elucidated. Therefore, the
aim of this work was to review the most relevant studies
published about phenytoin-induced GO (PGO) and outline
the possible mechanisms associated with this condition.2 ISRN Dentistry
2. Clinicaland Microscopic Featuresof the
Phenytoin-InducedGingivalOvergrowth
PGO can occur early within 3 months of the drug use and
it may reach a state of equilibrium often within the ﬁrst year
of the beginning of medication [13]. PGO seems to be more
prevalent in children and teenagers, but there is no diﬀerence
on its incidence in regard to gender or ethnic groups [14].
PGO incidence and severity is greater in the buccal sur-
face of both upper and lower anterior teeth [15]. Clinically,
gingival enlargement begins in the interdental papillae,
which increase and coalesce [16]. Tissue appearance may
range from a normal aspect to a hyperemic state [17].
Growth is slow but in more severe cases it may go so far as
to cover the whole tooth crown [13]. Few cases of PGO have
also been reported in edentulous patients [18] and around
deciduous teeth [14]. Likewise, there were some reports of
GO in areas of dental implants in patients taking phenytoin
[19].
MicroscopicanalysisofPGObiopsiesrevealsaredundant
tissueofapparentlyregularcompositionorwithanincreased
amount of collagen and number of ﬁbroblasts. Frequently,
the overlying surface epithelium presents rete pegs elongat-
ing into the underlying lamina propria [16]. The level of in-
ﬂammatory cell inﬁltrate varies signiﬁcantly [20].
3. Correlation between Phenytoin
PharmacologicalAspectsandGingival
Overgrowth
Many studies correlate the dose of phenytoin with PGO se-
verity [7, 21–23]. Some works suggest a possible positive
relationship once the reduction in the prescribed phenytoin
dose results in improvement of PGO severity [7]. Other
evidence is that patients who present more extensive gingival
lesions exhibit higher serum levels of phenytoin when com-
pared to those without PGO [7, 24, 25]. In contrast, some
reports showednocorrelationbetweenphenytoindaily dose,
treatment duration and severity of PGO [26–28]. Similarly,
some studies which investigated phenytoin levels in gingival
crevicular ﬂuid of epileptic patients were not able to detect
any signiﬁcant diﬀerence between PGO and control groups
[7, 21].
Given these controversial results, one should look for an-
other explanation for PGO beyond the increased levels of
circulating drug. Other theories are based on the hypothesis
ofadiﬀerentialtissueresponsetophenytoin,whichwouldbe
linked to genetic and environmental factors [29].
4. Pathogenesis of PGO
The mechanisms that trigger drug-induced GO have not
beencompletelyunderstoodand,althoughliteraturedataare
extensive, they are quite contradictory.
Some studies demonstrated that drugs such as phenytoin
and cyclosporine A are able to inhibit production of extra-
cellular matrix (ECM) by gingival ﬁbroblast and cell pro-
liferation in vitro [30, 31]. In contrast, others showed that
the accumulation of proteins in ECM, particularly collagen,
may occur due to an imbalance between the synthesis and
the degradation of ECM, being the possible cause of the GO
[32].
T h e r ei ss o m ee v i d e n c eo fd e c r e a s e dc o l l a g e np r o d u c t i o n
after phenytoin administration in vitro [33]. Likewise, Kato
et al. [34] showed a reduction in mRNA expression of col-
lagen type I and III associated with a higher density of these
ﬁbers in the PGO. These results suggest that the imbalance
thatleadstoPGOmightberelatedtodecreasedcollagendeg-
radation, not to an increase on its synthesis (Figure 1).
Collagen ﬁbers are degraded by two pathways: the extra-
celular one, which occurs by secretion of collagenases; and
the intracellular one, by collagen phagocytosis by ﬁbroblasts
[35]. In this regard, a common property of the 3 main classes
of drugs that induce GO—antiepileptic agents, immunosup-
pressants and calcium channel blockers—is that they aﬀect
calcium metabolism. These drugs induce a decrease in the
Ca2+ cell inﬂux (due to changes in the sodium-calcium ex-
change)leadingtoareductionintheuptakeoffolicacid,thus
limiting the production of active collagenase [36]( Figure 1).
In support to this hypothesis, a study showed that the
mRNA collagenase levels are diminished in drug-induced
overgrowntissuesofrats,withlesscollagendegradation[37].
Nevertheless, there is a controversy whether therapy with
folic acid would have a therapeutic eﬀect on PGO. Inoue and
Harrison [38] suggested that patients taking phenytoin and
a supplement of folic acid had GO prevented or eliminated.
Some other studies showed that patients receiving folate had
lower recurrence of gingival enlargement after its surgical re-
moval [39, 40]. In a recent study, Prasad et al. [41]e v a l u a t e d
60 patients and also concluded that therapy with folic acid is
able to delay and minimize GO. In opposition to these data,
Brown et al. [42] reported that folic acid was not eﬃcient as
a sole therapeutic agent in the reduction of PGO. Similarly,
Majola et al. [22] found that serum folate levels did not have
any signiﬁcant association with PGO. These contradictory
ﬁndings are not suﬃcient to indicate folic acid therapy as a
reliable alternative in the treatment of PGO.
In the extracellular collagen degradation pathway, other
matrix metalloproteinases (MMPs) than collagenase are also
responsible for the digestion of collagen ﬁbers [16]. The
enzymatic activities of MMPs are controlled by a tissue in-
hibitor (TIMP) whose function is to antagonize the actions
of MMPs [34]. In 2005, Kato et al. [34] showed that the gene
expression of MMP-1, 2, and 3 was reduced by phenytoin
administration, while the TIMP-1 mRNA was markedly aug-
mented. In accordance, macrophages pretreated with pheny-
toinandthenexposedtoLPShadlowerproductionofMMPs
than not treated controls [43]. Therefore, this reduction of
MMPs is believed to inﬂuence the PGO development.
Regarding the intracellular pathway of collagen degrada-
tion, phenytoin signiﬁcantly decreased collagen endocytosis,
which is related to a lower expression of α2β1-integrin [34].
Alpha-2-Beta-1-integrin functions as a speciﬁc receptor for
collagen type I in ﬁbroblasts and acts in the initial step of
collagen phagocytosis, providing an adhesive interaction
betweenﬁbroblastsandcollagen[35].Inthisregard,Kataoka
et al. [37] also demonstrated that integrin expression isISRN Dentistry 3
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Figure 1: Pathogenesis of phenytoin-induced gingival overgrowth. Several mechanisms are involved in the development of gingival
overgrowth. Phenytoin induces a decrease in the Ca2+ cell inﬂux leading to a reduction in the uptake of folic acid, thus limiting the
production of active collagenase. The drug decreases collagen endocytosis through induction of a lower expression of α2β1-integrin by
ﬁbroblasts. Myoﬁbroblasts seem to be stimulated by phenytoin. Other important elements directly responsible for phenytoin-induced
gingivalovergrowtharecytokines.Phenytoin-activatedﬁbroblastsproducelargeamountsofIL-6,IL-1,andIL-8.Suchmediatorsarecapable
of activating the proliferation of T cells and the recruitment of neutrophils to the involved tissues, establishing a direct interaction between
the immune system and the connective tissue. This interaction seems to be highly associated with ﬁbrotic diseases. Evidence also points
toward a role of dental plaque in the etiology of PGO through induction of a local inﬂammatory response, which is essential for the gingival
o v e r g r o w t h .G r o w t hf a c t o r ss u c ha sC T G F ,P D G F ,F G Fa n dT G F - β are found in higher levels in ﬁbrotic tissues and play a role in PGO.
Phenytoin may aﬀect the production of IL-13 by an activation of Th2 cells, as well as it may induce the release of TGF-β, CTGF and other
growth factors by macrophages, which leads, synergistically, to ﬁbroblast proliferation, collagen biosynthesis, activation of TIMPs, inhibition
of MMPs and ECM synthesis, characteristic processes observed in ﬁbrotic lesions. PDGF-β: platelet derived growth factor; FGF-2: ﬁbroblast
growth factor-2; TGF-β: transforming growth factor-β; CTGF: connective tissue growth factor; MMP: matrix metalloproteinase; TIMP:
tissue inhibitor of metalloproteinase.
diminished in ﬁbroblasts derived from GO tissues of rats
treated with cyclosporine, once more suggesting a role for
this pathway in GO (Figure 1). More recently, besides inte-
grins, the receptor uPARAP/ENDO180 was also described as
one of the main receptors responsible for collagen phago-
cytosis [44]. Nevertheless, there is no experimental evidence
indicating that this receptor is aﬀected by drugs such as phe-
nytoin.
The possible role of phenytoin on ﬁbroblasts growth and
death has also been investigated [45]. During healing, the
transition from a granulation tissue to a remodeling tissue
requires the apoptosis of ﬁbroblasts. In wounds with in-
adequate apoptosis the formation of ﬁbrotic tissues may oc-
cur. Thus, modulation of apoptosis could contribute to f-
ibrosis in gingival tissues. The study of Kantarci et al. [45]
demonstrated that ﬁbroblast apoptosis is decreased in GO,
and that this decrease may contribute to ﬁbrosis, particularly
in PGO. Thus, increased number of ﬁbroblasts and ECM ac-
cumulation appears to be due, in part, to diminished ﬁ-
broblast death in these tissues [46].4 ISRN Dentistry
Inconclusion,pathogenesisofPGOinvolvesadecreasein
collagen degradation which is related to alterations in cal-
cium metabolism, levels of MMPs and TIMPs, integrins ex-
pression and ﬁbroblast apoptosis.
5. Role of Inﬂammation and Growth Factors in
PGO
An interesting aspect of PGO is that tissues become more
ﬁbrotic and have lower levels of inﬂammation [29]. There-
fore, the nature of such overgrowth is close to a ﬁbrosis proc-
ess that can occur in various organs such as liver, lung and
skin[46].Soitispossibletoevaluatesomefeaturesofﬁbrotic
lesions to better understand PGO.
Fibrosis usually results from chronic inﬂammation—in
which inﬂammation, tissue remodeling and repair processes
occur simultaneously [46]. Usually there is a persistent irri-
tant agent that can be infectious, chemical, physical or me-
chanical. The repair process involves two stages: a regenera-
tivephaseandaphaseknownasﬁbrosis,inwhichconnective
tissues replace normal parenchyma. This phase can become
harmful if not properly controlled, resulting in an excessive
deposition of ECM [47].
Gingival tissues remain frequently in a state of injury
and repair, which involves repetitive cycles of production of
chemotactic factors, recruitment of inﬂammatory cells and
remodeling. Tissue repair and remodeling are regulated by
cytokines and chemokines produced by inﬂammatory cells
such as macrophages and lymphocytes and to a lesser extent
by ﬁbroblasts [29]. Based on these ﬁndings, many studies
have focused on the role of cytokines and growth factors in
thepathogenesisofdrug-inducedGO.Ithasbeenshownthat
phenytoin, nifedipine, and cyclosporine may regulate the ex-
pression of cytokines in gingival tissues [48].
Some cytokines and growth factors were found in higher
levels in gingival overgrown tissues, including interleukin-
6 (IL-6), IL-1, platelet derived growth factor-β (PDGF-β),
ﬁbroblast growth factor-2 (FGF-2), transforming growth
factor-β (TGF-β) and connective tissue growth factor
(CTGF) [49–51]( Figure 1).
TGF-β is a cytokine secreted by several cell types, in-
cluding macrophages, and with an important role in regu-
lating the collagen metabolism in the connective tissues by
stimulating collagen biosynthesis [52]. TGF-β is stored with-
in the cell as a homodimer, noncovalently bound to a protein
called latency-associated protein (LAP), which maintains
TGF-β inactive. The dissociation of TGF-β and LAP is cat-
alyzed by several agents, such as cathepsins and MMPs. IL-
13 induces the formation of latent TGF-β and also the pro-
duction of both cathepsins and MMPs that cleave LAP
and activate TGF-β [47]. However the eﬀects of TGF-β on
gingival tissues are surprisingly low if compared with other
connective tissues [53]. The hypothesis to explain such ﬁnd-
ing is that the eﬀects of TGF-β in the metabolism of ECM
are mediated by CTGF, which is found at high levels in sev-
eral ﬁbrotic diseases [29]. It was already demonstrated that
CTGF levels are increased in PGO tissues [51] and CTGF
was also shown to stimulate ﬁbroblast proliferation and
ECM synthesis. As demonstrated, there is a requirement to
simultaneously use CTGF and TGF-β in skin to induce ﬁbro-
sis [54]. Thus, neither of the two factors alone was able to
initiate the ﬁbrotic processes. CTGF is rapidly and potently
induced by TGF-β and contributes to the regulation of some
genes in the ECM [55]. Although CTGF is continuously
present in the tissue, TGF-β is only found in the initial pe-
riods, indicating that there may be a cascade eﬀect [51]. The
mechanism by which CTGF promotes ﬁbrosis has been in-
vestigated and a possible interaction with integrins has also
been proposed [56]( Figure 1).
A recent study shows a possible association between GO
and epithelial mesenchymal transition (EMT) [57]. EMT is a
process in which epithelial cells trans-diﬀerentiate into ﬁ-
broblast-like cells. TGF-β1 is a potent inducer of EMT in a
variety of tissues and CTGF expression is increased in cells
undergoing EMT [57]. Then, the observation of elevated
levels of EMT markers in the PGO lesions could suggest the
EMT contribution in human GO and ﬁbrosis [57].
Experimental studies in animals also have demonstrated
a role for Th2-immune responses and cytokines IL-4, IL-13,
IL-5, and IL-21 in ﬁbrotic processes [47]. Interestingly, phe-
nytoin has complex eﬀects on the immune system and it
was already observed an induction of Th2 response by this
drug. Phenytoin-treated mice were shown to have increased
production of IL-4 and decreased levels of IL-1α and
Interferon-γ (IFN-γ)[ 58].
Phenytoin also increases the production of IL-6 and IL-8
by ﬁbroblasts [8]. IL-6 is capable of activating the prolifera-
tion of T and B cells, and it has been associated with ﬁbrosis
invariousorgans.TheincreaseofIL-6levelsseemstoinvolve
the cyclooxygenase-2 (COX-2) pathway [59]( Figure 1).
IL-8 is chemotactic for polymorphonuclear neutrophils
(PMN) and T cells and it has also been associated with
ﬁbrosis in the liver and kidney [60, 61]. The number of PMN
and T cells is increased in gingival tissues induced by pheny-
toin [62], so phenytoin could contribute to the increased
recruitment and activation of these cells by upregulation of
IL-6 and IL-8 [8].
Besides cytokines, other important proteins involved in
PGO development are cathepsins and lysosomal proteases,
responsible for digestion of 90% of cellular proteins. A rare
congenital disease, mucolipidoses II, characterized by im-
pairment on cathepsin maturation and, thus, by reduction of
its activity, has the GO as one of its features [63]. An in vitro
study showed that phenytoin and cyclosporine can inhibit
the production of cathepsin L, but not B, by gingival ﬁbro-
blasts [63] and transgenic mice deﬁcient for cathepsin L
spontaneously develop GO [64].
Another interesting element linking systemic ﬁbrotic dis-
eases to GO is the presence of myoﬁbroblasts in phenytoin-
induced tissues [65]. Myoﬁbroblasts are highly diﬀerentiated
cells that secrete large quantities of collagen and are involved
in the tissue repair process [47] .T h ep r e s e n c ea n dr o l eo f
myoﬁbroblastsinotherﬁbroticdiseases,suchasskinﬁbrosis,
were already known [47]. The presence of myoﬁbroblasts
in PGO suggests that this drug exacerbates the normal
tissue turnover/wound healing signals responsible for the
appearance of myoﬁbroblasts [65].ISRN Dentistry 5
Based on these ﬁndings, it is possible to conclude that the
processthatleadstoPGOinvolvesaﬁneregulationofgrowth
factors and inﬂammatory cytokines, as shown for other ﬁ-
brotic diseases. Understanding the relationship of the im-
munesystemwiththeﬁbroticprocessandhowphenytoinaf-
fectsitseemstobeacrucialsteptocontrolthisphenomenon.
6. BacterialBioﬁlm andPGODevelopment
The role of dental plaque as a co-factor in the etiology of
PGO was recognized in the latest periodontal disease classi-
ﬁcation system [66]. In such classiﬁcation system, the “drug-
induced gingival diseases” were categorized into the major
group “dental plaque-induced gingival diseases” and their
development and severity were pointed as being inﬂuenced
by the accumulation of dental plaque [66].
Despite this classiﬁcation system, the literature is still
controversial whether the oral bioﬁlm is important to trigger
or to worsen GO. Some studies have found signiﬁcant cor-
relations between the incidence and/or severity of GO and
the amount of accumulated dental plaque and calculus [67,
68]. Other studies have shown that satisfactory oral hygiene
is able to reduce the overgrowth, but not to completely pre-
vent it [69, 70]. A possible involvement of some bacteria spe-
cies in the gingival lesion development was previously stud-
ied. Takada et al. [71] found that Prevotella intermedia (Pi)
prevalence is higher in patients with PGO than in patients
taking the medication but who did not develop that injury,
and also those who did not use phenytoin. Akiyama et al.
[72] also examined subgingival bacterial proﬁles in subjects
taking phenytoin who exhibited, or not, PGO. Quantitative
analysis performed before and after periodontal treatment,
revealed two bacterial species signiﬁcantly associated with
PGO, Treponema denticola (Td) and Porphyromonas gingi-
valis (Pg). Miyazaki also found increased levels of Td and
Pg in severely aﬀected PGO sites [73]. These ﬁndings are in
contrast to the studies of Yamada et al. [24] and Smith et
al. [74] who did not ﬁnd diﬀerences in the oral microbial
population of patients with and without PGO. By examining
these conﬂicting data it does not seem reasonable to assume
that there is a speciﬁc group or speciﬁc bacteria that lead
t oG O .M o r es t u d i e sa r ew a r r a n t e di nt h i sﬁ e l di no r d e rt o
clarify the role of bacteria on PGO.
In addition to bacteria itself the host response to these
antigensalsomayberelatedtoPGOandhasreceivedincreas-
ing attention. The bacterial components in dental plaque can
be recognized by host cell Toll-like receptors (TLRs), which
are sensors of pathogen-associated molecular patterns [75].
In this regard, phenytoin demonstrated some modulating ef-
fects over the TLRs. An in vitro study using hamster cells
treated with phenytoin and cyclosporine showed opposite
results for these two substances. While cyclosporine in-
creased signaling by TLR2 and TLR4, phenytoin decreased
this signaling with lower expression of adhesion molecules
such as CD54 [75]. Recognition of the cell-wall components
peptidoglycan and lipoproteins by TLR2 and recognition of
the outer membrane component lipopolysaccharide (LPS)
by TLR4 lead to a series of events, including nuclear factor
(NF)-κB activation, that results in cytokine production and
expression of adhesion molecules in ﬁbroblasts [75]. The re-
duction in cell signaling induced by phenytoin may alter the
inﬂammatory response in gingival tissues, favoring bacterial
invasion and proliferation and, therefore, may be an impor-
tant factor in the pathogenesis of PGO. Here, it seems rea-
sonable to conclude that the interaction between dental
plaque and the host response to it has a role in the etiology
of PGO, but this relationship is not completely elucidated.
7.GeneticFactorsAssociatedwithPGO
As mentioned before, not all patients taking phenytoin de-
velop PGO. Evidence suggests that genetic factors also might
have a signiﬁcant role in the pathogenesis of PGO and in the
patient’s susceptibility to this unwanted eﬀect. A genetic pre-
disposition could inﬂuence a variety of factors in the drug-
plaque-induced inﬂammation. These include gingival ﬁbro-
blast functional heterogeneity, collagenolytic activity, drug
metabolism and collagen synthesis [17, 76].
One study examined the prevalence and correlation of
the polymorphism of integrin genes and drug-induced GO
[35]. It has been shown that patients with the genotype C
807 showed lower expression of integrins and those with GO
hadahigherfrequencyoftheallele807C,suggestingthatthe
integrin has a critical role in the induction of drug-induced
GO [35].
Regarding drug metabolism, the cytochrome P450
(CIP2C9 and 2C19) is responsible for phenytoin conversion
on its hydroxylated form in the liver [25]. Pharmacogenetic
inﬂuences on drug metabolism have been widely reviewed
and gene polymorphism of cytochrome P450 2C19 appeared
to be responsible for much of the interindividual variability
on drug elimination [77]. Polymorphisms in CIP2C9 were
reportedandparticularlythe2C9∗3po l ym o rp h i s mh a sbee n
suggested to exert great inﬂuence on the metabolism of phe-
nytoin, so it was hypothesized to be a candidate gene for
prevention and early diagnosis of the GO severity [78]. Soga
et al. [25] showed in a study with 28 patients taking pheny-
toin that those who had the expression of the polymorphism
CIP2C9∗3 had higher serum concentrations of phenytoin.
However, among patients with this polymorphism only a
small proportion exhibited GO.
In relation to ﬁbroblasts, since 1981 Hassell [79]s t i m -
ulated the discussion about possible phenotypic diﬀerences
between gingival ﬁbroblasts. It has been speculated that
drug-induced GO may occur due to direct or indirect stim-
ulation of the proliferation of some populations of ﬁbrob-
lasts, called “responsive”, which somehow justiﬁed the indi-
vidual susceptibility to those drugs [80–82]. Cell culture
studies made with monozygous and dizygous twins have
conﬁrmed the functional heterogeneity of gingival ﬁbrob-
lasts [82].
8. Concluding Remarks
The review of various investigations into the pathogenesis
of drug-induced GO supports the hypothesis that it is a6 ISRN Dentistry
side eﬀect with a multifactorial etiology. The inﬂammatory
changesthatoccurwithingingivaltissuesseemtoorchestrate
the interaction between drugs and ﬁbroblasts.
Further studies arerequiredfora better understanding of
the aspects of gingival extracellular matrix metabolism and
theinteractionsbetweendrugs,immuneresponse,cytokines,
growth factors and gingival cells. As treatment and preven-
tion of drug-induced GO remains unsatisfactory, for some
patients, the change in drug therapy should be considered, a
plaque control program might be performed and, in some
cases, surgical elimination of the gingival tissue must be
unavoidable yet. A thorough understanding of the pathogen-
esis of this unwanted side eﬀect is essential if we are to devise
appropriate regimens for its prevention and treatment.
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